2-(吡啶-3-基)噻唑-4-羰酰氯 | 180992-31-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(吡啶-3-基)噻唑-4-羰酰氯
• 英文名称: 2-(3-pyridinyl)-1,3-thiazole-4-carbonyl chloride
• 英文别名: 2-(3-pyridinyl)thiazole-4-carbonyl chloride；2-pyridin-3-yl-thiazole-4-carbonyl chloride；4-Thiazolecarbonyl chloride, 2-(3-pyridinyl)-；2-pyridin-3-yl-1,3-thiazole-4-carbonyl chloride
• CAS: 180992-31-8
• 化学式: C₉H₅ClN₂OS
• 分子量: 224.671
• InChiKey: JTYSZJURMOQRTP-UHFFFAOYSA-N

物化性质

• 沸点：
  389.5±48.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-(吡啶-3-基)噻唑-4-羰酰氯 、 2-(二氟甲氧基)苯胺 在 base 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 N-[2-(difluoromethoxy)phenyl]-2-pyridin-3-yl-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  IRAK-4 inhibitors. Part 1: A series of amides

  摘要：

  The synthesis and pro. le of a series of amides are described. Some of these compounds were potent IRAK-4 inhibitors and two examples were evaluated in vivo. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.058
• 作为产物：
  描述：

  2-(3-吡啶基)噻唑-4-羧酸 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 生成 2-(吡啶-3-基)噻唑-4-羰酰氯
  参考文献：
  名称：

  Novel Heterocyclic Compounds as Pesticides

  摘要：

  本发明涉及新颖的杂环化合物，其制备过程以及用于控制动物害虫的用途，包括节肢动物，尤其是昆虫。

  公开号：

  US20120094837A1

文献信息

• 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
  申请人：——

  公开号：US20020035103A1

  公开（公告）日：2002-03-21

  Compounds of formula I 1 are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands. Also disclosed are histamine-3 receptor ligand compositions and methods of antagonizing or agonizing histamine-3 receptors.

  公式I1的化合物在治疗由组织胺-3受体配体防止或改善的疾病或病况中非常有用。还公开了组织胺-3受体配体组合物和拮抗或激动组织胺-3受体的方法。
• [EN] QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS COMME INHIBITEURS DE RTK DE TAM
  申请人：QURIENT CO LTD

  公开号：WO2016166250A1

  公开（公告）日：2016-10-20

  The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.

  本发明涉及一种新型化合物，它们是TAM（Axl、Mer和Tyro 3）和/或Met家族受体酪氨酸激酶（RTKs）的抑制剂。这些化合物适用于治疗与TAM家族受体相关的、伴随的、由其引起的或诱导的疾病，特别是其过度功能。这些化合物适用于治疗高增殖性疾病，如癌症，特别是免疫抑制性癌症、难治性癌症和癌症转移。
• 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
  申请人：——

  公开号：US20020137931A1

  公开（公告）日：2002-09-26

  Compounds of formula I 1 are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands. Also disclosed are histamine-3 receptor ligand compositions and methods of antagonizing or agonizing histamine-3 receptors.

  公式I1的化合物在治疗由组胺-3受体配体防止或改善的疾病或症状中很有用。还披露了组胺-3受体配体组合物和拮抗或激动组胺-3受体的方法。
• Tricyclic thieno-azepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05654297A1

  公开（公告）日：1997-08-05

  This invention relates to new bicyclic non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.

  本发明涉及新的双环非肽类利尿激素拮抗剂，可用于治疗希望降低利尿激素水平的情况，例如充血性心力衰竭、肾脏过度水分重吸收的疾病状况以及血管阻力增加和冠状动脉收缩的情况。
• Fused heterocyclic azepines as vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05696112A1

  公开（公告）日：1997-12-09

  This invention relates to bicyclic non-peptide vasopressin antagonists useful in treating conditions where decreased vasopressin levels are desired, in conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction, the compounds of this invention having the core structure of ##STR1## wherein: E--Y is selected from the moieties --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, and ##STR2## the moiety ##STR3## includes an optionally substituted, fused 6-membered heterocyclic aromatic ring containing two nitrogen atoms, a fused 5-membered heterocyclic aromatic ring containing either a) one heteroatom selected from O, S or N; b) two N atoms; or one N atom and one O or S atom; and R.sup.1, R.sup.2, R.sup.3 and R.sub.b are as defined herein.

  本发明涉及双环非肽类加压素拮抗剂，用于治疗需要降低加压素水平的情况，以及肾脏过度水分重吸收和血管阻力增加和冠状血管收缩的情况。本发明化合物具有以下核心结构：##STR1## 其中：E-Y是选择自基团--CH.dbd.CH--，--CH.sub.2 CH.sub.2--和##STR2## 基团##STR3##包括一个可选取代的融合6元杂环芳香环，其中包含两个氮原子，一个融合的5元杂环芳香环，包含a）一个从O、S或N中选择的杂原子；b）两个N原子；或一个N原子和一个O或S原子；以及R1、R2、R3和Rb的定义如本文所述。